ReviewPediatric pulmonology2012
Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia.
Review in Pediatric pulmonology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 79 citations in OpenAlex.
- Long-term pulmonary outcomes in BPD throughout the life-course.Journal of perinatology : official journal of the California Perinatal Association · 2026Review
- Detection of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia using oxygen saturation data.Pediatric research · 2025Article
- Multiomics endotyping of preterm infants with bronchopulmonary dysplasia and pulmonary hypertension-A pilot study.Pulmonary circulation · 2023Article
- Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Endotypes of Prematurity and Phenotypes of Bronchopulmonary Dysplasia: Toward Personalized Neonatology.Journal of personalized medicine · 2022Review
- Insulin-like growth factor-1: A potential target for bronchopulmonary dysplasia treatment (Review).Experimental and therapeutic medicine · 2022Review
- Simvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia-Induced Bronchopulmonary Dysplasia via the KLF2-Mediated Mechanism.Oxidative medicine and cellular longevity · 2022Article
- Optimizing ventilator support in severe bronchopulmonary dysplasia in the absence of conclusive evidence.Frontiers in pediatrics · 2022Article
- Characteristics of Children with Bronchopulmonary Dysplasia with Prolonged and/or Later-Onset Pulmonary Hypertension.Annals of the American Thoracic Society · 2021Article
- Understanding hydrogen sulfide signaling in neonatal airway disease.Expert review of respiratory medicine · 2021Review
- Outcomes of neonates with tracheostomy secondary to bronchopulmonary dysplasia.BMC pediatrics · 2020Article
- Phenotypes of Bronchopulmonary Dysplasia.International journal of molecular sciences · 2020Review
- Longitudinal Analysis of Pulmonary Function in Survivors of Congenital Diaphragmatic Hernia.The Journal of pediatrics · 2020Article
- The Transitional Heart: From Early Embryonic and Fetal Development to Neonatal Life.Fetal diagnosis and therapy · 2020Review
- Spectrum of Current Management of Pediatric Pulmonary Hypertensive Crisis.Critical care explorations · 2019Article
- Inflammatory Response of Pulmonary Artery Smooth Muscle Cells Exposed to Oxidative and Biophysical Stress.Inflammation · 2018Article
- [Research progress in drug therapy for bronchopulmonary dysplasia in preterm infants].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018Review
- Pulmonary hypertension's variegated landscape: a snapshot.Pulmonary circulation · 2017Review
- Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia.The Journal of pediatrics · 2017Article
- Oxygen weaning after hospital discharge in children with bronchopulmonary dysplasia.Pediatric pulmonology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Pulmonary hypertension (PH) is an increasingly recognized complication of premature birth and bronchopulmonary dysplasia (BPD), and is associated with increased morbidity and mortality. Extreme phenotypic variability exists among preterm infants of similar gestational ages, making it difficult to predict which infants are at increased risk for developing PH. Intrauterine growth retardation or drug exposures, postnatal therapy with prolonged positive pressure ventilation, cardiovascular shunts, poor postnatal lung and somatic growth, and genetic or epigenetic factors may all contribute to the development of PH in preterm infants with BPD. In addition to the variability of severity of PH, there is also qualitative variability seen in PH, such as the variable responses to vasoactive medications. To reduce the morbidity and mortality associated with PH, a multi-pronged approach is needed. First, improved screening for and increased recognition of PH may allow for earlier treatment and better clinical outcomes. Second, identification of both prenatal and postnatal risk factors for the development of PH may allow targeting of therapy and resources for those at highest risk. Third, understanding the pathophysiology of the preterm pulmonary vascular bed may help improve outcomes through recognizing pathways that are dysregulated in PH, identifying novel biomarkers, and testing novel treatments. Finally, the recognition of conditions and exposures that may exacerbate or lead to recurrent PH is needed to help with developing treatment guidelines and preventative strategies that can be used to reduce the burden of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.